Methods for predicting irinotecan toxicity
作者： Mark J. Ratain , Anna Di Rienzo , Carrie Grimsley , Federico Innocenti
DOI:
关键词: Irinotecan 、 Ugt1a1 gene 、 Bioinformatics 、 Genotype 、 Linkage disequilibrium 、 Toxicity 、 Cancer 、 Medicine
摘要: The present invention concerns the methods and compositions for evaluating risk of ironotecan toxicity in a cancer patient based on genotype at position −3156 UGT1A1 gene or any linkage disequilibrium with variant.
google.co.in参考文章(231)
C A Chen, H Okayama, Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA BioTechniques. ,vol. 6, pp. 632- 638 ,(1988)
Lévesque E, Bélanger A, Hum Dw, Beaulieu M, Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics. ,vol. 9, pp. 207- 216 ,(1999)
Mark Ratain, Lalitha Iyer, Michael Sawyer, Federico Innocenti, Soma Das, Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity ,(2002)
Deborah Rund, Idit Azar, Olga Shperling, A Mutation in the Promoter of the Multidrug Resistance Gene ( MDR1 ) in Human Hematological Malignancies may Contribute to the Pathogenesis of Resistant Disease Advances in Experimental Medicine and Biology. ,vol. 457, pp. 71- 75 ,(1999) , 10.1007/978-1-4615-4811-9_9
Ida S. Owens, Joseph K. Ritter, Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Progress in Nucleic Acid Research and Molecular Biology. ,vol. 51, pp. 305- 338 ,(1995) , 10.1016/S0079-6603(08)60882-X
Anne Chew, Julie Y. Choi, Eileen Rounds, Beena Koshy, Haplotypes of the ugt1a1 gene ,(2001)
Barbara G. Lubejko, Louise B. Grochow, David S. Ettinger, Susan E. Sartorius, Ross C. Donehower, Eric K. Rowinsky, Michael K. Rock, Tian-Ling Chen, Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks Cancer Research. ,vol. 54, pp. 427- 436 ,(1994)
Mark J. Ratain, Elora Gupta, Xiaolin Wang, Ahmad R. Safa, Pharmacokinetic Modulation of Irinotecan and Metabolites by Cyclosporin A Cancer Research. ,vol. 56, pp. 1309- 1314 ,(1996)
Shin-ichi Akiyama, Hisaaki Shimazu, Kiyotomo Seto, Kiyoshi Niwa, Sonshin Takao, Kazutaka Yamada, Tamotsu Matsumoto, Norimasa Shudo, Tatsuhiko Furukawa, Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo- 1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3 -pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin. Cancer Research. ,vol. 52, pp. 3655- 3660 ,(1992)
Frank H. Ruddle, Kevin L. Bentley, Gualberto Ruano, Genome anthologies for harvesting gene variants ,(1997)